Shots:
- Diagonal has dosed the first patient with DIAG723, a clustering agonist antibody, in P-I/II (DIAMOND) trial (n=~93) for people living with hereditary hemorrhagic telangiectasia (HHT)
- Trial will evaluate DIAG723 (SC) vs PBO in 3 parts: Part A (P-I) will assess single ascending doses; Part B (P-II) will evaluate multiple doses over 14wks. for safety & preliminary efficacy, incl. nosebleed frequency/severity & hematological parameters
- Part C (P-II) will evaluate multiple doses of DIAG723 in HHT pts with coexisting pulmonary arterial hypertension, assessing safety and exploratory effects on HHT and pulmonary-related measures
Ref: Globenewswire | Image: Diagonal Therapeutics | Press Release
R
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
